{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:47:16Z","timestamp":1792370836831,"version":"4.4.0"},"reference-count":94,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Purpose of Review\nAntipsychotics are the standard of care when it comes to the treatment of Schizophrenia, and they are often used in Bipolar as well. Their use can come with adverse effects such as extrapyramidal movements, metabolic complications as well as cardiovascular complications such as a prolonged QT interval. Treatment for these side effects ranges from the treatment of the complications up to the cessation of the medication, which could come at the expense of the user\u2019s stability. Both schizophrenia and bipolar disorder have an increased risk of suicide and increased morbidity. The purpose of this review presents the background, evidence, and indications for the use of the new second-generation antipsychotic Cariprazine, which has a primary function as a D3 and D2 partial agonist, with higher selectivity for the D3 receptor type.\nRecent Findings\nSchizophrenia is currently teated by dopamine antagonists and\/or 5HT modulators, each with their own set of side effects. Bipolar disorder is mostly treated with mood stabilizers. Studies looking at the efficacy and safety of cariprazine have shown in two phase II trials and phase III trials the decrease in PANSS scores in schizophrenia. The most common adverse effects were akathisia, insomnia, constipation, and other extrapyramidal side effects. A unique side effect of Cariprazine caused bilateral cataract and cystic degeneration of the retina in the dog following daily oral administration for 13 weeks and\/or 1 year and retinal degeneration in rats following daily oral administration for 2 years. Another study showed that cariprazine had significant efficacy in preventing relapse in patients with schizophrenia. The time to the loss of sustained remission was significantly longer (P = .0020) for cariprazine compared to placebo (hazard ratio = 0.51) during the double-blind treatment. 60.5% of patients treated with cariprazine and 34.9% of patients treated with placebo sustained remission through the final visit (odds ratio [OR] = 2.85; P = .0012; number needed to treat [NNT] = 4. Another Phase IIIb study looked at negative symptoms and used the Positive and Negative Syndrome Scale Factor Score for Negative Symptoms (PANSS-FSNS), and it found that the use of cariprazine, from baseline to week 26, led to a greater least-squares mean change in PANSS-FSNS than did risperidone. Another study looked at the quality of life years with the treatment of cariprazine and showed those treated with cariprazine had superior quality of life compared to those treated with risperidone. In terms of bipolar disorder, it showed a decrease in depressive symptoms as measured by decreased MADRs scores with a dose of 3.0mg\/day. A phase II study looked at the use of cariprazine in mania or mix states and showed cariprazine significantly decreased YMRS scores compared to placebo, least-square mean difference of \u20136.1 (p &lt; 0.001). The metabolic parameters demonstrated comparable changes except for fasting glucose in which cariprazine was associated with elevations in glucose levels compared to placebo (p &lt; 0.05). Another phase III study showed significant differences in YMRS total score mean change between cariprazine versus placebo-treated group. Changes in metabolic profiles in all mentioned studies were minimal.\nSummary\nCariprazine, in recent studies, has shown some promise in being able to treat both bipolar disorder in manic, depressed, and mixed states as well as schizophrenia. Side effects noted as adverse events in these studies are similar in profile to the medications that were developed in the past. With better relapse prevention, cariprazine could be a reasonable alternative clozapine.<\/jats:p>","DOI":"10.64719\/pb.4374","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"83-117","source":"Crossref","is-referenced-by-count":3,"title":["Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults"],"prefix":"10.64719","volume":"50","author":[{"given":"Amber","family":"Edinoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam T.","family":"Ruoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya T.","family":"Ghaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Rezayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanshi","family":"Jani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse M.","family":"Cornett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S et al. Definition and description of schizophrenia in the DSM-5 [Internet]. Vol. 150, Schizophrenia Research. Schizophr Res. 2013:3\u201310. [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23800613\/","DOI":"10.1016\/j.schres.2013.05.028"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Black DW, Boffeli TJ. Simple schizophrenia: Revisited. Compr Psychiatry. 1990;31(4):344\u2013349. [Internet] [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/2387146\/","DOI":"10.1016\/0010-440X(90)90041-P"},{"key":"ref3","unstructured":"The structure of negative symptoms within schizophrenia: implications for assessment \u2013 PubMed [Internet]. [cited 2020 Jul 25]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16254064\/"},{"key":"ref4","unstructured":"The NIMH-MATRICS consensus statement on negative symptoms \u2013 PubMed [Internet]. [cited 2020 Jul 25]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16481659\/"},{"key":"ref5","unstructured":"Schizophrenia: a concise overview of incidence, prevalence, and mortality \u2013 PubMed [Internet]. [cited 2020 Jul 25]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18480098\/"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Brown S. Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry. 1997;171:502\u2013508. [Internet] Royal College of Psychiatrists. [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9519087\/","DOI":"10.1192\/bjp.171.6.502"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: A reexamination. Arch Gen Psychiatry. 2005;62:247\u2013253. [Internet] Archives of General Psychiatry. [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15753237\/","DOI":"10.1001\/archpsyc.62.3.247"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Carpenter WT, Bartko JJ, Carpenter CL, Strauss JS. Another View of Schizophrenia Subtypes: A Report From the International Pilot Study of Schizophrenia. Arch Gen Psychiatry. 1976;33(4):508\u2013516. [Internet] [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/938187\/","DOI":"10.1001\/archpsyc.1976.01770040068012"},{"key":"ref9","unstructured":"Classical subtypes for schizophrenia: literature review for DSM-IV \u2013 PubMed [Internet]. [cited 2020 Jul 25]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/1822677\/"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Carpenter WT, Tandon R. Psychotic disorders in DSM-5. Summary of changes. Asian J Psychiatr. 2013 Jun;6(3):266\u2013268. [Internet] [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23642992\/","DOI":"10.1016\/j.ajp.2013.04.001"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. The Lancet. 2016;387:1561\u20131572. [Internet] Lancet Publishing Group. [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26388529\/","DOI":"10.1016\/S0140-6736(15)00241-X"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Gonda X, Pompili M, Serafini G, Montebovi F, Campi S, Dome P et al. Suicidal behavior in bipolar disorder: Epidemiology, characteristics and major risk factors. J Affect Disord. 2012;143:16\u201326. [Internet] Journal of Affective Disorders. [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22763038\/","DOI":"10.1016\/j.jad.2012.04.041"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Tondo L, Isacsson G, Baldessarini RJ. Suicidal behaviour in bipolar disorder: Risk and prevention. CNS Drugs. 2003;17:491\u2013511. [Internet] CNS Drugs. [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12751919\/","DOI":"10.2165\/00023210-200317070-00003"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Betzler F, St\u00f6ver LA, Sterzer P, K\u00f6hler S. Mixed states in bipolar disorder\u2013changes in DSM-5 and current treatment recommendations. International Journal of Psychiatry in Clinical Practice. 2017;21:244\u2013258. [Internet] Taylor and Francis Ltd. [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28417647\/","DOI":"10.1080\/13651501.2017.1311921"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M et al. A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry. 2017 Dec 1;74(12):1206\u20131213. [Internet] [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29049482\/","DOI":"10.1001\/jamapsychiatry.2017.2943"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors \u2013 IUPHAR review 13. Br J Pharmacol. 2015;172(1):1\u201323. [Internet] [cited 2020 Jul 25] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25671228\/","DOI":"10.1111\/bph.12906"},{"key":"ref17","unstructured":"van de Leemput J, Hess JL, Glatt SJ, Tsuang MT. Genetics of Schizophrenia: Historical Insights and Prevailing Evidence. Adv Genet. 2016;96:99\u2013141. [Internet] [cited 2020 Jul 26] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27968732\/"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Harrison PJ, Geddes JR, Tunbridge EM. The Emerging Neurobiology of Bipolar Disorder. Trends in Neurosciences. 2018;41:18\u201330. [Internet] Elsevier Ltd. [cited 2020 Jul 26] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29169634\/","DOI":"10.1016\/j.tins.2017.10.006"},{"key":"ref19","unstructured":"Epidemiology and risk factors of schizophrenia \u2013 PubMed [Internet]. [cited 2020 Jul 26]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26994378\/"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"H\u00e4fner H, An Der Heiden W. Epidemiology of schizophrenia. Canadian Journal of Psychiatry. 1997;42:139\u2013151. [Internet] Canadian Psychiatric Association. [cited 2020 Jul 26] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9067063\/","DOI":"10.1177\/070674379704200204"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ferrari AJ, Stockings E, Khoo JP, Erskine HE, Degenhardt L, Vos T et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016 Aug 1;18(5):440\u2013450. [Internet] [cited 2020 Jul 26] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27566286\/","DOI":"10.1111\/bdi.12423"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Chen P, Dols A, Rej S, Sajatovic M. Update on the Epidemiology, Diagnosis, and Treatment of Mania in Older-Age Bipolar Disorder. Current Psychiatry Reports. 2017;19 [Internet] Current Medicine Group LLC 1. [cited 2020 Jul 26]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28647815\/","DOI":"10.1007\/s11920-017-0804-8"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Khandaker GM, Dantzer R. Is there a role for immune-to-brain communication in schizophrenia? Psychopharmacology. 2016;233:1559\u20131573. [Internet] Springer Verlag. [cited 2020 Jul 27] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26037944\/","DOI":"10.1007\/s00213-015-3975-1"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J. 2008 Apr;22(4):982\u20131001. [Internet] [cited 2020 Jul 27] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18056830\/","DOI":"10.1096\/fj.07-9326rev"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Lewis G, David A, Andr\u00e9assson S, Allebeck P. Schizophrenia and city life. Lancet. 1992 Jul 18;340(8812):137\u2013140. [Internet] [cited 2020 Jul 27] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/1352565\/","DOI":"10.1016\/0140-6736(92)93213-7"},{"key":"ref26","unstructured":"Howes OD, McDonald C, Cannon M, Arseneault L, Boydell J, Murray RM. Pathways to schizophrenia: The impact of environmental factors. In: International Journal of Neuropsychopharmacology. Int J Neuropsychopharmacol. 2004 [Internet] [cited 2020 Jul 27]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/14972079\/"},{"key":"ref27","unstructured":"Epidemiology and risk factors of schizophrenia \u2013 PubMed [Internet]. [cited 2020 Jul 27]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26994378\/"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Hirschfeld RM. Differential diagnosis of bipolar disorder and major depressive disorder. Journal of Affective Disorders. 2014;169:S12\u201316. Elsevier BV.","DOI":"10.1016\/S0165-0327(14)70004-7"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Jones A, Jones M. Reviewing depot injection efficacy in the treatment of schizophrenia. Nurs Stand. 2016 Apr 13;30(33):50\u201359.","DOI":"10.7748\/ns.30.33.50.s45"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M et al. Discovery of \u03b2-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488\u201318493. [Internet] [cited 2020 Jul 28] Available from: \/pmc\/articles\/PMC3215024\/?report=abstract.","DOI":"10.1073\/pnas.1104807108"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C. Improving Current Treatments for Schizophrenia. Drug Dev Res. 2016 Nov 1;77(7):357\u2013367. [Internet] [cited 2020 Jul 28] Available from: http:\/\/doi.wiley.com\/10.1002\/ddr.21337.","DOI":"10.1002\/ddr.21337"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"St\u0119pnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018;23 [Internet] MDPI AG. [cited 2020 Jul 28]. Available from: \/pmc\/articles\/PMC6222385\/?report=abstract.","DOI":"10.3390\/molecules23082087"},{"key":"ref33","unstructured":"Smith T, Weston C, Lieberman J. Schizophrenia (Maintenance Treatment) American Family Physician. 2010 Aug;82 [Internet] [cited 2020 Jul 28]. Available from: www.clinicalevidence."},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"M\u00f6ller HJ, Czobor P. Pharmacological treatment of negative symptoms in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. 2015;265:567\u2013578. [Internet] Dr. Dietrich Steinkopff Verlag GmbH and Co. KG. [cited 2020 Jul 28] Available from: https:\/\/link.springer.com\/article\/10.1007\/s00406-015-0596-y.","DOI":"10.1007\/s00406-015-0596-y"},{"key":"ref35","unstructured":"M\u00f6ller H-J. THE RELEVANCE OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA AND HOW TO TREAT THEM WITH PSYCHOPHARMACEUTICALS? 2016;28 Psychiatria Danubina."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis. Br J Psychiatry. 2010 Sep;197(3):174\u2013179. [Internet] [cited 2020 Jul 28] Available from: www.r-project.org.","DOI":"10.1192\/bjp.bp.109.067710"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Emsley R, Kilian S, Phahladira L. How long should antipsychotic treatment be continued after a single episode of schizophrenia? Curr Opin Psychiatry. 2016 May 1;29(3):224\u20139. [Internet] [cited 2020 Jul 28] Available from: http:\/\/journals.lww.com\/00001504-201605000-00008.","DOI":"10.1097\/YCO.0000000000000249"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry. 2006 Apr 1;63(4):426\u2013432. [Internet] [cited 2020 Jul 28] Available from: https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/209506.","DOI":"10.1001\/archpsyc.63.4.426"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Mueser KT, Glynn SM, Cather C, Xie H, Zarate R, Smith LF et al. A Randomized Controlled Trial of Family Intervention for Co-occurring Substance Use and Severe Psychiatric Disorders. Schizophr Bull. 2013;39(3):658\u2013672. [Internet] [cited 2020 Jul 28] Available from: https:\/\/academic.oup.com\/schizophreniabulletin\/article-abstract\/39\/3\/658\/1884607.","DOI":"10.1093\/schbul\/sbr203"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"De Witte NAJ, Crunelle CL, Sabbe B, Moggi F, Dom G. Treatment for Outpatients with Comorbid Schizophrenia and Substance Use Disorders. A Review. Eur Addict Res. 2014;20(3):105\u2013114. [Internet] [cited 2020 Jul 28] Available from: https:\/\/www.karger.com\/Article\/FullText\/355267.","DOI":"10.1159\/000355267"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, Meht\u00e4l\u00e4 J, Hoti F, Jedenius E et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017 Jul 1;74(7):686\u2013693. [Internet] [cited 2020 Jul 28] Available from: https:\/\/jamanetwork.com\/","DOI":"10.1001\/jamapsychiatry.2017.1322"},{"key":"ref42","unstructured":"Rang & Dale\u2019s Pharmacology \u2013 Google Books [Internet]. [cited 2020 Jul 28]. Available from: https:\/\/www.google.com\/books\/edition\/Rang_Dale_s_Pharmacology\/s2R-ZYz_iBYC?hl=en&gbpv="},{"key":"ref43","unstructured":"Brenner and Stevens\u2019 Pharmacology E-Book \u2013 Google Books [Internet]. [cited 2020 Jul 28]. Available from: https:\/\/www.google.com\/books\/edition\/Brenner_and_Stevens_Pharmacology_E_Book\/v3g4DwAAQBAJ?hl=en&gbpv=0."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP et al. Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation. Antipsychotic Drugs in Resistant Schizophrenia. [cited 2020 Jul 28]; Available from: https:\/\/academic.oup.com\/schizophreniabulletin\/article-abstract\/32\/4\/715\/1934800.","DOI":"10.1093\/schbul\/sbj067"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Muscatello MRA, Bruno A, De Fazio P, Segura-Garcia C, Pandolfo G, Zoccali R. Augmentation strategies in partial responder and\/or treatment-resistant schizophrenia patients treated with clozapine. Informa Healthcare. 2014;15:2329\u20132345. [Internet] Expert Opinion on Pharmacotherapy. [cited 2020 Jul 28] Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1517\/14656566.2014.956082.","DOI":"10.1517\/14656566.2014.956082"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Bobo WV. The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. Mayo Clinic Proceedings. 2017;92:1532\u201351. doi: 10.1016\/j.mayocp.2017.06.022. [Internet] Elsevier Ltd. [cited 2020 Jul 28] Available from:","DOI":"10.1016\/j.mayocp.2017.06.022"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Correll CU, Leucht S, Kane JM. Reviews and Overviews Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies. Am J Psychiatry. 2004;161 [Internet] [cited 2020 Jul 28]. Available from: http:\/\/ajp.psychiatryonline.org.","DOI":"10.1176\/appi.ajp.161.3.414"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Glue P, Herbison P. Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: Network meta-analysis. Aust N Z J. Psychiatry. 2015 Dec 6;49(12):1215\u20131220. [Internet] [cited 2020 Jul 28] Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26546499.","DOI":"10.1177\/0004867415614109"},{"key":"ref49","unstructured":"Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW et al. The International Society for bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013 Nov 1;170(11):1249\u20131262. [Internet] [cited 2020 Jul 28] Available from: \/pmc\/articles\/PMC4091043\/?report=abstract."},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Thase ME. Antidepressants and rapid-cycling bipolar II disorder: dogma, definitions and deconstructing discrepant data. Br J Psychiatry. 2013 Apr;202(4):251\u20132. [Internet] [cited 2020 Jul 28] Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23549940.","DOI":"10.1192\/bjp.bp.112.120550"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand. 2014 Dec 1;130(6):452\u2013469. [Internet] [cited 2020 Jul 28] Available from: http:\/\/doi.wiley.com\/10.1111\/acps.12343.","DOI":"10.1111\/acps.12343"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Selle V, Schalkwijk S, V\u00e1zquez GH, Baldessarini RJ. Treatments for acute bipolar depression: Meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014 Feb 18;47(2):43\u201352. [Internet] [cited 2020 Jul 28] Available from: http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0033-1363258.","DOI":"10.1055\/s-0033-1363258"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, N\u00e9meth G et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016 Mar 1;173(3):271\u2013281. [Internet] [cited 2020 Jul 28] Available from: http:\/\/ajp.psychiatryonline.org\/doi\/10.1176\/appi.ajp.2015.15020164.","DOI":"10.1176\/appi.ajp.2015.15020164"},{"key":"ref54","unstructured":"Pfennig A, Bschor T, Falkai P, Bauer M. Clinical practice guideline: The diagnosis and treatment of bipolar disorder-recommendations from the current S3 guideline. Dtsch Arztebl Int. 2013 Feb 8;110(6):92. [Internet] [cited 2020 Jul 28] Available from: \/pmc\/articles\/PMC3583180\/?report=abstract."},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: Analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry. 2008;9(3):198\u2013211. [Internet] [cited 2020 Jul 28] Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/15622970701317265.","DOI":"10.1080\/15622970701317265"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Weisler RH, Calabrese JR, Thase ME, Arvekvist R, Stening G, Paulsson B et al. Efficacy of Quetiapine Monotherapy for the Treatment of Depressive Episodes in Bipolar I Disorder: A Post Hoc Analysis of Combined Results From 2 Double-Blind, Randomized, Placebo-Controlled Studies. J Clin Psychiatry. 2008 May 11;69(5):769\u2013782.","DOI":"10.4088\/JCP.v69n0510"},{"key":"ref57","unstructured":"Mental Health Medications | NAMI: National Alliance on Mental Illness [Internet]. [cited 2020 Jul 28]. Available from: https:\/\/www.nami.org\/About-Mental-Illness\/Treatments\/Mental-Health-Medications\/Types-of-Medication\/Cariprazine-(Vraylar)"},{"key":"ref58","unstructured":"Vraylar (cariprazine) dosing, indications, interactions, adverse effects, and more [Internet]. [cited 2020 Jul 28]. Available from: https:\/\/reference.medscape.com\/drug\/vraylar-cariprazine-999874."},{"key":"ref59","unstructured":"And -----------------------Warnings, Precautions---------------------. HIGHLIGHTS OF PRESCRIBING INFORMATION [Internet]. [cited 2020 Jul 28]. Available from: www.fda.gov\/medwatch."},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016 Apr 1;21(2):123\u2013127. doi: 10.1017\/S1092852916000043. [Internet] [cited 2020 Jul 28] Available from:","DOI":"10.1017\/S1092852916000043"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Citrome L. Cariprazine for the treatment of schizophrenia: A Review of this dopamine D3-Preferring D3\/D2 receptor partial agonist. Walsh Medical Media, LLC. 2016;10:109\u2013119. [Internet] Clinical Schizophrenia and Related Psychoses. [cited 2020 Jul 28] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27440212\/","DOI":"10.3371\/1935-1232-10.2.109"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Weso\u0142owska A, Partyka A, Jastrz\u0119bska-Wi\u0119sek M, Ko\u0142aczkowski M. The preclinical discovery and development of cariprazine for the treatment of schizophrenia. Expert Opin Drug Discov. 2018 Aug 3;13(8):779\u2013790. [Internet] [cited 2020 Jul 28] Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/17460441.2018.1471057.","DOI":"10.1080\/17460441.2018.1471057"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Citrome L. Cariprazine in schizophrenia: Clinical efficacy, tolerability, and place in therapy. American Psychiatric Association. 2013;30:114\u2013126. [Internet] Advances in Therapy. [cited 2020 Jul 28] Available from: www.advancesintherapy.com.","DOI":"10.1007\/s12325-013-0006-7"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Citrome L. Cariprazine: Chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opinion on Drug Metabolism and Toxicology. 2013;9:193\u2013206. [Internet] Taylor & Francis. [cited 2020 Jul 28] Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1517\/17425255.2013.759211.","DOI":"10.1517\/17425255.2013.759211"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Gyerty\u00e1n I, Kiss B, S\u00e1ghy K, Laszy J, Szab\u00f3 G, Szabados T et al. Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011 Nov 1;59(6):925\u2013935.","DOI":"10.1016\/j.neuint.2011.07.002"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B et al. Cariprazine Exhibits Anxiolytic and Dopamine D 3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model. Int J Neuropsychopharmacol. 2017;20(10):788\u2013796. [Internet] [cited 2020 Jul 28] Available from: https:\/\/academic.oup.com\/ijnp\/article-abstract\/20\/10\/788\/3845232.","DOI":"10.1093\/ijnp\/pyx038"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Kiss B, Horv\u00e1th A, N\u00e9methy Z, Schmidt \u00c9, Laszlovszky I, Bugovics G et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D 3\/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: In vitro and neurochemical profile. J Pharmacol Exp Ther. 2010 Apr 1;333(1):328\u2013340. [Internet] [cited 2020 Jul 28] Available from: http:\/\/jpet.aspetjournals.org\/content\/333\/1\/328.","DOI":"10.1124\/jpet.109.160432"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuro-Psychopharmacology Biol Psychiatry. 2003 Oct 1;27(7):1081\u20131090.","DOI":"10.1016\/j.pnpbp.2003.09.004"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Mis Iak B, Bie\u0144kow S K I P, Samochowiec J. Cariprazine-a novel antipsychotic drug and its place in the treatment of schizophrenia. doi: 10.12740\/PP\/OnlineFirst\/80710. [cited 2020 Jul 28]; Available from:","DOI":"10.12740\/PP\/OnlineFirst\/80710"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Mazza M, Marano G, Traversi G, Carocci V, Romano B, Janiri L. Cariprazine in Bipolar Depression and Mania: State of the Art. CNS Neurol Disord \u2013 Drug Targets. 2018 Aug 28;17(10):723\u2013727. [Internet] [cited 2020 Jul 28] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30152291\/","DOI":"10.2174\/1871527317666180828120256"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I et al. Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. 2018;57:1493\u20131528. [Internet] Clinical Pharmacokinetics. Springer International Publishing. [cited 2020 Jul 28] Available from: https:\/\/link.springer.com\/article\/10.1007\/s40262-018-0664-3.","DOI":"10.1007\/s40262-018-0664-3"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"De Deurwaerd\u00e8re P. Cariprazine: New dopamine biased agonist for neuropsychiatry disorders. Drugs of Today. 2016 Feb 1;52(2):97\u2013110.","DOI":"10.1358\/dot.2016.52.2.2461868"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K et al. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results from an International, Phase III Clinical Trial. J Clin Psychopharmacol. 2015;35(4):367\u2013373.","DOI":"10.1097\/JCP.0000000000000346"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Durgam S, Litman RE, Papadakis K, Li D, N\u00e9meth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. Int Clin Psychopharmacol. 2016 Jan 28;31(2):61\u201368. [Internet] [cited 2020 Jul 28] Available from: \/pmc\/articles\/PMC4736298\/?report=abstract.","DOI":"10.1097\/YIC.0000000000000110"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Nakamura T, Kubota T, Iwakaji A, Imada M, Kap\u00e1s M, Morio Y. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment) Drug Des Devel Ther. 2016;10:327\u2013338.","DOI":"10.2147\/DDDT.S95100"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Durgam S, Starace A, Li D, Migliore R, Ruth A, N\u00e9meth G et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Schizophr Res. 2014 Feb 1;152(2\u20133):450\u2013457.","DOI":"10.1016\/j.schres.2013.11.041"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I et al. Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015 Dec;76(12):e1574\u20131582.","DOI":"10.4088\/JCP.15m09997"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl) 2017;234(2):199\u2013209.","DOI":"10.1007\/s00213-016-4450-3"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016;176(2\u20133):264\u2013271.","DOI":"10.1016\/j.schres.2016.06.030"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Cutler AJ, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: Results from a 1-year open-label study. CNS Spectr. 2018;23(1):39\u201350.","DOI":"10.1017\/S1092852917000220"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"N\u00e9meth G, Laszlovszky I, Czobor P, Szalai E, Szatm\u00e1ri B, Hars\u00e1nyi J et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103\u20131113.","DOI":"10.1016\/S0140-6736(17)30060-0"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"N\u00e9meth B, Moln\u00e1r A, Akehurst R, Horv\u00e1th M, K\u00f3czi\u00e1n K, N\u00e9meth G et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J Comp Eff Res. 2017;6(8):639\u2013648.","DOI":"10.2217\/cer-2017-0024"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y et al. efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res. 2019;204:282\u2013288.","DOI":"10.1016\/j.schres.2018.08.020"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Correll CU, Potkin SG, Zhong Y, Hars\u00e1nyi J, Szatm\u00e1ri B, Earley W. Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia. J Clin Psychiatry. 2019 Jan;80(2):0\u20130.","DOI":"10.4088\/JCP.18m12495"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Fleischhacker W, Galderisi S, Laszlovszky I, Szatm\u00e1ri B, Barab\u00e1ssy \u00c1, Acsai K et al. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58(2019):1\u20139.","DOI":"10.1016\/j.eurpsy.2019.01.015"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Calabrese JR, Keck PE, Starace A, Lu K, Ruth A, Laszlovszky I et al. Efficacy and safety of low- and high-dose Cariprazine in acute and mixed mania associated with bipolar i disorder: A double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284\u2013292.","DOI":"10.4088\/JCP.14m09081"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S. Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II\/III trials. Eur Neuropsychopharmacol. 2015;25(11):1882\u20131891.","DOI":"10.1016\/j.euroneuro.2015.08.020"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I et al. Cariprazine in the treatment of acute mania in bipolar i disorder: A double-blind, placebo-controlled, Phase III trial. J Affect Disord. 2015;174:296\u2013302.","DOI":"10.1016\/j.jad.2014.11.018"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Durgam S, Starace A, Li D, Migliore R, Ruth A, N\u00e9meth G et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: A phase II trial. Bipolar Disord. 2015;17(1):63\u201375.","DOI":"10.1111\/bdi.12238"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Earley W, Durgam S, Lu K, Ruth A, N\u00e9meth G, Laszlovszky I et al. Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. J Affect Disord. 2018;226(July):239\u2013244.","DOI":"10.1016\/j.jad.2017.09.040"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"McIntyre RS, Masand PS, Earley W, Patel M. Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. J Affect Disord. 2019;257(July):600\u2013606.","DOI":"10.1016\/j.jad.2019.07.020"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Earley W, Burgess MV, Rekeda L, Dickinson R, Szatm\u00e1ri B, N\u00e9meth G et al. Cariprazine treatment of bipolar depression: A randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry. 2019;176(6):439\u2013448.","DOI":"10.1176\/appi.ajp.2018.18070824"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I et al. efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2018;33(6):312\u2013321.","DOI":"10.1097\/YIC.0000000000000235"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I et al. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. J Affect Disord. 2018;225(February):350\u2013356.","DOI":"10.1016\/j.jad.2017.08.040"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:26:59Z","timestamp":1791314819000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/cariprazine-to-treat-schizophrenia-and-bipolar-disorder-in-adults\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":94,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4374","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}